Over 200 years of experience
in the pharmaceutical industry
FDF, API, CMO, CDMOPharmaceutical development and manufacturing
-
Contract manufacturing
Learn moreWe specialise in the production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Our production lines for highly potent medicines (OEB 5) are among the most advanced in Central and Eastern Europe. We operate in full compliance with EU cGMP, FDA and EAEU standards.
-
Laboratory services
Learn moreWe offer comprehensive preformulation and analytical support. In 2025, we launched a state-of-the-art laboratory for highly potent parenteral products (OEB 5). Our team performs over 4,000 tests annually.
Over 50 products in 130 forms and doses
We manufacture prescription (Rx) medicines – antibiotics, human insulins, CNS and dermatological products – as well as over-the-counter (OTC) medicines, dietary supplements and dermocosmetics. Every year, we deliver over 25 million packages to hospitals, pharmacies and healthcare institutions, supporting the health and well-being of patients worldwide.
View portfolioWe manufacture in Poland
– for a safer tomorrow
We are the oldest pharmaceutical company in Poland and one of the oldest in Europe. Since 1823, we have been building the foundations of Polish pharmacy by introducing groundbreaking solutions. We were the first in the country to start producing penicillin, insulin and antibiotics, setting new standards in treatment. Today, we produce 10% of the medicines classified as critical by the European Union, helping to secure treatment access for millions of patients.
News
-
23.10.2025AnnouncementsCenter for Development and Production of Highly Potent Drugs
TZF Polfa, a Polish pharmaceutical manufacturer, proudly presents its latest venture in Warsaw – the Center for Development and Production of Highly Potent Drugs, one of the most advanced injectable drug manufacturing facilities in Europe. This technologically advanced plant fully meets the growing global demand for injectable medicines in various pharmaceutical forms. The facility covers […]Read more -
02.04.2026UncategorizedTZF Polfa and Ecopia – Cooperation to Enhance Access to Medicines in Ethiopia
TZF Polfa S.A. has signed a Letter of Intent (LOI) with Ecopia, initiating cooperation aimed at developing the pharmaceutical market in Ethiopia and improving access to critically important medicines. The agreement marks the first step toward building a long-term partnership, combining TZF Polfa’s expertise in development, manufacturing, and regulatory compliance with Ecopia’s experience in the […]Read more -
02.04.2026UncategorizedTZF Polfa S.A. i Ecopia podpisują list intencyjny (LOI) – współpraca na rzecz rozwoju dostępu do leków w Etiopii
TZF Polfa S.A., jeden z kluczowych producentów farmaceutycznych w Europie, podpisała list intencyjny (LOI) z firmą Ecopia, rozpoczynając współpracę ukierunkowaną na rozwój rynku farmaceutycznego w Etiopii oraz zwiększenie dostępności leków o znaczeniu krytycznym. Porozumienie stanowi pierwszy etap budowy długoterminowego partnerstwa, łączącego kompetencje TZF Polfa w zakresie rozwoju, produkcji i zgodności regulacyjnej z doświadczeniem Ecopia w […]Read more -
06.03.2026TendersRequest fot quotatnion – RFQ Z2/5438/1 – Study monitoring – Empagliflozin
In connection with the implementation of the project 2022/ABM/04/00014-00 – „Opracowanie i rozwój produktu leczniczego z substancją czynną EMPAGLIFLOZYNĄ – leku generycznego na cukrzycę typu 2” (”Design and development of a medicinal product with the active substance EMPAGLIFLOZIN – a generic drug for type 2 diabetes”), Tarchominskie Zakłady Farmaceutyczne POLFA S.A. invites you to submit […]Read more -
05.03.2026Announcements
Selection procedure for the position of President of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of President of the Management Board. Written applications should be sent by post to the Company’s address (Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., ul. A. Fleminga 2, 03-176 Warsaw) or delivered in person […]Read more -
05.03.2026Announcements
Selection procedure for the position of First Member of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of First Member of the Management Board. Written applications should be sent by post or delivered in person to the Company Authorities Support Department (ul. A. Fleminga 2, 03-176 Warsaw) by March […]Read more -
05.03.2026Announcements
Selection procedure for the position of Second Member of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of Second Member of the Management Board. Written applications should be sent by post to the Company’s address (Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., ul. A. Fleminga 2, 03-176 Warsaw) or delivered in […]Read more -
20.01.2026For patients
Availability of Elenium
Warsaw, January 20, 2026 Elenium Availability Dear Sir or Madam, Following the administrative decision of the Chief Pharmaceutical Inspectorate to withdraw from the market certain batches of the medicinal product: Elenium 5 mg, coated tablets Elenium 10 mg, coated tablets Elenium 25 mg, coated tablets we would like to provide […]Read more
